Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Dec 2023 Results (n=1413) a meta-analysis from this and NCT03099031, NCT01164046 and NCT01130025 studies on individual patient level data to report the rate of rVTE and MB by 6 months according to site of cancer from prospective studies involving CAT patients on tinzaparin, presented at the 65th American Society of Hematology Annual Meeting and Exposition
30 Nov 2019 New trial record
06 Nov 2019 Results describing prescription and use of the anticoagulant treatment beyond 6 months and up to 12 months and to measure clinical outcomes in Cancer-associated Thrombosis patients initially treated with tinzaparin in 2 trials (NCT02898051, NCT03099031) released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com